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Abstract 
BACKGROUND: Nationwide more than 90% of cervical cancer cases are caused by the human 
papilloma virus (HPV).  Cervical cancer can be largely prevented by administration of the HPV 
vaccine for children before becoming sexually active. However, vaccination rates in the United 
States, remain low at 60%, and only 39.7% through series of completion, despite the strong 
evidence to support the effectiveness of the HPV vaccine.  Research indicates a clinician’s 
recommendation, providing information and opportunity for discussion about the vaccine are 
strong motivators for parents to vaccinate their children, regardless of ethnicity.  This study 
addresses the barriers to parent/caregiver intent to vaccinate, and clinician time to discuss the 
vaccine, by implementing an RN-led educational intervention regarding the HPV vaccine for 11-
17 year-old children.  
Purpose:  The purpose of this study is to evaluate the effect of an RN-led educational 
intervention on 1) parent/caregiver intent to initiate the HPV vaccination 2) to evaluate effect on 
HPV vaccination rates, and 3) evaluate satisfaction with the education provided in a pediatric 
primary care clinic.   
Methods: The design was a multi-phased quasi- experimental pre/post baseline assessment study 
that had 4 phases: a chart review (Phase 1), a study introduction (staff meeting: Phase 2), an 
educational intervention (Phase 3), and an outcome evaluation (Phase 4). The RN-led education 
intervention focused on the caregiver of adolescent children to address questions and barriers 
regarding the HPV vaccine. The setting for all phases of the study were done at a pediatric 
primary care clinic in Southern Indiana. The clinic is responsible for the management and 
treatment of pediatric patients. The sample for the study included: any caregivers of 11-17 year-
old children being seen in the office for a non-acute visit.  These children had never received any 
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doses of the HPV vaccine and were English speaking. Exclusion criteria was any caregiver of a 
11-17 years of age being seen for a sick visit, or any that had previously received any dose of the 
HPV vaccine. Evaluation methods included: chart audit tool that recorded child demographics, 
information on HPV counseling provided, a pre- and post- educational survey to measure 
knowledge, intent to vaccinate, and evaluation of the educational intervention. 
Results:  Pre- intervention surveys indicated most parents had heard of HPV vaccinations (80%), 
knew that it was recommended (87%), and felt it was part of cancer prevention (100%).  While 
scores increased, there were no significant differences between pre- versus post-educational 
intervention surveys in caregivers who intended to have their child receive the vaccination today 
(M=4.3 vs M=6.7) or in the future (M=5.9 vs 6.9). The HPV vaccination rates for the initial dose 
of the vaccine increased from 19.1% to 40.8%, and for any dose from 58.4% to 64.3%.  These 
results indicate the clinic surpassed their goal of 60% after the intervention was provided.  Post-
survey results showed caregiver evaluation was favorable when measuring satisfaction and 
helpfulness with educational intervention provided.  Vaccination rates improved after a 1:1 brief 
educational discussion between the caregiver the RN; this finding suggests that the 1:1 
interaction to discuss facts and answer questions may be associated with improved vaccination 
rates. 
Conclusion:  HPV vaccination rates increased after a brief educational intervention regarding the 
HPV vaccine was provided to caregivers of 11-17 year-old children.  This finding suggests that 
education may have been beneficial; however, overall vaccination rates were still low and the 
need for improvement remains. Future work should seek to identify which specific elements of 
this intervention contributed to the success and strategies to sustain the improvements as well as 
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identify additional strategies to further improve vaccination rates. An important next step is to 
initiate efforts to increase vaccine series completion rates.  
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Introduction 
More than ninety percent of cervical cancer cases are caused by the human papilloma 
virus (HPV). The Center for Disease Control (CDC; 2019) reports 300,000 cervical precancerous 
cases, 44,000 cervical cancer cases, and 4,000 deaths related to HPV every year in the United 
States.  Human Papilloma Virus affects men as well as women.  Every year in the U.S 25,000 
women and 19,000 men get cancers caused by HPV, comprising nearly four out of every ten 
cancer diagnoses caused by the virus (CDC, 2019). Cervical cancer was once the leading cause 
of cancer deaths among women in the U.S., but the HPV vaccine and cervical cancer screening 
have made it one of the most preventable cancers. Screening alone will not protect men or 
women from HPV cancers. The HPV vaccination helps prevent these cancers by preventing the 
infections that cause them (CDC, 2019).  
Cancers and diseases secondary to the human papilloma virus (HPV) may be prevented 
through the administration of the HPV vaccination. However, vaccination coverage percentages 
remain below the standards set by the Healthy People 2020 initiatives (Harris, 2017). These 
initiatives set a goal that 80 percent of adolescent boys and girls from ages 13 to 15 years should 
receive the three-dose series of the HPV vaccine through completion (Smulian, Mitchell, & 
Stokley, 2016). At present, however, approximately only 60 percent of girls and boys ages 13 to 
17 years have received only one dose of the vaccination; and only 39.7% received the 
vaccination through to completion of all three doses (Smulian, Mitchell, & Stokley, 2016). In 
2014, the rates among boys aged 13 to 17 years were considerably lower with 41.7% receiving 
only the first dose, and only 21.6% completing the three-dose series (Smulian, Mitchell, & 
Stokley, 2016).  Therefore, it is imperative that primary care providers work toward efforts to 
increase vaccination coverage.  
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In a 2014 study, Holman found that lack of parental knowledge of vaccination was a 
major barrier to providing the HPV vaccine to adolescents. For example, a significant number of 
parents in that study reported needing more information before vaccinating their children. The 
parents voiced concerns about the vaccine’s effect on sexual behavior and demonstrated a low 
perception of their children’s risk of contracting HPV. These parents also identified social 
influences, irregular preventive care, and vaccine cost as potential barriers. Additionally, some 
parents of sons reported not vaccinating their sons because of the perceived lack of direct benefit. 
Parents consistently cited health care professionals’ recommendations as one of the most 
important factors in their decision to vaccinate their children (Holman, 2014).  In a 2011 study,  
the proportion of physicians who reported “always” recommending HPV vaccine was 40% for 
early adolescent girls, 55.3% for middle adolescents, and 51.8% for late adolescents/young 
adults (Vadaparampil, 2011). A study from the CDC (2019) states that providers identified that 
limited staff resources, challenges of electronic health records, issues with state immunization 
registries, patient misinformation about vaccines and vaccine stigma, cultural/language barriers, 
competing priorities, levels of funding, staff buy-in, training needs, and low health literacy were 
barriers to recommending the HPV vaccine (CDC, 2019).   
Continued efforts are needed to ensure that health care professionals and parents 
understand the importance of vaccinating adolescents before they become sexually active. 
Research suggests that further efforts are also needed to reduce missed opportunities for HPV 
vaccination when adolescents interface with the health care system.  A study from the American 
Academy of Pediatrics (2014) concluded that many missed opportunities for HPV vaccination 
occur not because parents and providers feel that vaccination is unimportant but because both 
parties tacitly agree to delay vaccination until there is a perception that the adolescent is at risk 
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for sexual activity (AAP, 2014).  Health care professionals may benefit from guidance on 
communicating HPV recommendations to patients and parents. Dempsey (2019) and Chuang  
(2017) suggest future practices should include continuing education for providers on the 
importance of educating parent/caregivers of adolescents ages 11-17 years old using improved 
information technologies (IT) techniques (Dempsey, 2019).  Chuang (2017) also recommends 
placing posters and prompts in the exam rooms and in their individual office spaces as a way of 
providing additional education on the vaccine to parents/caregivers.   
Purpose 
This project was initiated to improve rates of the administration of the HPV vaccination 
in the pediatric primary care setting. The setting for the study was the St. Vincent Pediatric 
Clinic in Salem, Indiana. The clinic identified that at their current 58.4% vaccination rate, they 
were falling short of their goal of 60% of patients receiving the HPV vaccine each month. The 
ultimate clinic target goal was set at 80% to meet the Healthy People 2020 goal of and 80% HPV 
vaccination rate (Harris, 2017).  The providers at the clinic verbalized the need for an 
intervention to aid in meeting their target monthly goal. They recommended patient/caregiver 
education because they identified the lack of education as a major barrier.  
This project implemented and evaluated a parent/caregiver educational intervention to 
increase intent to vaccinate and evaluate vaccination rates among 11-17- year-old adolescent 
patients and their caregivers.  The specific aims were to evaluate the effect of an RN- led 
educational intervention on: 
1) Caregiver intent to initiate the HPV vaccine for their child 
2) HPV vaccination rates for the clinic 
3) Satisfaction with the educational intervention provided to the caregivers 
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Theoretical Framework 
The theoretical framework that shaped and contributed best to the design of this study 
was the Consolidated Framework for Implementation Research (CFIR; Garbutt, 2018). Garbutt 
(2018) used the CFIR to develop a pragmatic intervention to increase implementation of the 
HPV vaccine guideline recommendation and HPV vaccination rates in pediatric primary care 
practices (Garbutt, 2018). The CFIR was used to systematically investigate and characterize 
factors that may strongly influence vaccine use. Then the Behavior Change Wheel (BCW) and 
the Theoretical Domains Framework (TDF) were used to analyze provider behavior and identify 
behaviors to target for change and behavioral change strategies to include in the intervention. 
The BCW and TDF identified facilitators and barriers to guideline use across the five CFIR 
domains: most distinguishing factors related to provider characteristics, their perception of the 
intervention, and their process to deliver the vaccine. The CFIR domains using the theory 
included: intervention characteristics, outer setting, inner setting, characteristics of individuals, 
and process. Targeted behaviors using this theory suggested that providers should recommend 
the HPV vaccine the same way and at the same time as the other adolescent vaccines, to answer 
parents’ questions with confidence, and to implement a vaccine delivery system (Garbutt, 2018).  
According to Garbutt (2018), the intervention should be aimed at improving provider’s 
capability (knowledge, communication skills) and motivation (action planning, belief about 
consequences, social influences) regarding implementing guideline recommendations, and 
increasing their opportunity to do so (vaccine delivery system).  Behavior change strategies 
included: providing more information, adding communication skill training with graded tasks 
and modeling, feedback of coverage rates, goal setting, and social support. The theory 
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demonstrates strategies that were combined in an implementation intervention to be delivered 
using practice facilitation, educational outreach visits, and cyclical small tests of change.  
This framework was consistent with goals set forth for this study. Using the CFIR theory 
and the associated BCW and TDF helped facilitate the development of a pragmatic, multi-
component implementation intervention to increase use of the HPV vaccine in the primary care 
setting.  These implementation strategies, according to theory, should be adopted into the 
primary care offices to increase the use of clinical recommendations towards the HPV vaccine. 
Methods 
The study design was a multi-phased quasi experimental pre/post baseline assessment 
study that had 4 phases: a chart review (Phase 1), a study introduction (staff meeting: Phase 2), 
an educational intervention (Phase 3), and an outcome evaluation (Phase 4). The project focused 
on working with the parent/caregiver of adolescent children to address questions and barriers 
regarding the HPV vaccine. Providing education and an opportunity to discuss questions and 
answers with the parent/caregiver may help to overcome knowledge deficit and correct 
misinformation.  Overcoming barriers by providing an educational discussion may have an 
impact on intent to initiate the HPV vaccination, therefore, leading to an increase in HPV 
vaccination rates. 
Setting  
The setting for all phases of the study was St. Vincent Pediatric Clinic located in Salem, 
Indiana. The clinic is part of a large healthcare organization, Ascension Healthcare. Annually, 
the clinic is responsible for the management and treatment of pediatric patients in Southern 
Indiana. This clinic is responsible for the management and treatment of pediatric patients.  The 
clinic staff consisted of: two APRN’s, one RN, two MA’s, and a front desk receptionist.  On 
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average between the two providers they see approximately 70 patients per week.  The clinic 
baseline rate of any dose of the HPV vaccine was 58.4%.  They were falling short of their goal of 
60% of adolescents receiving the HPV vaccine each month with the ultimate goal of reaching the 
Healthy People 2020 initiative of 80% of the adolescents being vaccinated (Harris, 2017). The 
providers at the clinic verbalized the need for an intervention to aid in meeting their targeted 
monthly goal and they suggested caregiver education. The providers identified a lack of 
knowledge amongst caregivers, and the providers felt they do not have time to discuss the 
vaccine during the visit. Therefore, this project implemented and evaluated an RN led caregiver 
educational intervention to increase intent to vaccinate and evaluate vaccination rates in the 
clinic. 
Sample 
For phase one, a convenience sample of 100 chart reviews were completed on medical 
records from patient charts dated October 15, 2019 through January 15, 2020 were reviewed to 
determine the clinic’s baseline HPV vaccination rate.  Criteria for inclusion in the educational 
intervention study were any parent/caregiver of a child 11-17 years of age being seen in the 
office for a non-acute visit.  Exclusion criteria for the study included 1) any parent/caregiver of a 
child 11-17 years of age being seen for a sick visit, 2) any parent/caregiver of a child that is non-
English speaking, and 3) any parent/caregiver of a child that does not meet age criteria of 11-17 
years old.  Variables that were included in the chart review were whether counseling was 
provided, who provided vaccine counseling, whether the vaccine was offered by the provider, 
whether the patient accepted/declined/deferred vaccination, if the vaccine series was initiated, 
and if it was completed.  Gender, age, and race were also recorded.  A chart audit tool was used 
to record this information (Appendix D).  
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Phase four of the study was done after one month of providing the educational intervention. 
The follow-up chart review evaluated vaccination rates for adolescents seen in the office by a 
provider during the time period of January 15, 2020 to February 15, 2020.  The post-chart audit 
included a convenience sample of 100 chart reviews on medical records dated January 15, 2020 
to February 15, 2020.  The charts were reviewed until a sufficient sample size of 100 was 
reached.  Inclusion and exclusion criteria were the same for both pre- and post- audit chart 
reviews.   
Procedures 
The study started with a baseline chart review to establish current vaccination rates.  The 
study goal was to educate 120 parents/caregivers on the significance of initiation of the first dose 
of the HPV vaccine during their well-child exam. The DNP project was implemented at this 
location to aid in increasing first dose HPV vaccination rates and provide an RN-led educational 
intervention to improve intent to vaccinate by providing a question and answer session with the 
parent/caregiver, therefore helping the office increase vaccination rates and reach their current 
goal.  
Phase 1 – Chart Review  
Phase 1 included a chart review of recent medical records to determine the baseline 
vaccination rate at the clinic.  One hundred medical records were randomly selected from charts 
dated October 15, 2019 through January 15, 2020 meeting age criteria 11-17 years old until a 
sufficient sample size of 100 was obtained.  Variables that were determined by reviewing the 
chart included whether vaccine counseling was provided, who provided vaccine counseling, 
whether the vaccine was offered by the provider, whether the patient accepted/declined/deferred 
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vaccination, if the vaccine series was initiated, and if it was completed. Gender, age, and race 
were also recorded. A chart audit tool was used to record this information (Appendix D).  
Phase 2 – Study Introduction/Staff Meeting 
Once the chart review was completed, a staff meeting was held (Phase 2). All staff 
working in the clinic as providers, nurses, medical assistants, and/or at front desk were invited to 
attend the staff meeting through flyers posted in the office. There were 6 possible participants 
including: 2 APRN’s as providers, 1 RN, 2 MA’s, and one front desk receptionist. Invitation to 
staff meeting attached (Appendix J). All clinic staff were informed of the study using a script as 
a guide for the discussion (Appendix K).  The purpose of the staff meeting was to inform them of 
the educational intervention that was going to be provided by the PI in the clinic. Educational 
pamphlets and pre- / post- educational intervention surveys were discussed to familiarize the 
staff with the content the PI was planning to provide to caregivers.  
Additionally, the staff meeting was designed to inform the staff of their current baseline 
rate of vaccination and to describe the educational intervention and process that was going to be 
provided by the PI in the clinic. The clinic staff was not involved in conducting the study. 
Educational pamphlets (Appendix G) and pre-/ post- surveys (Appendices E and Appendix F) 
were discussed to familiarize the staff of the content the PI was planning to provide to 
parents/caregivers. Any questions the staff had regarding the educational intervention were 
answered by the PI.  
Phase 3 – Clinic-Led Educational Intervention  
The first contact with the parent/caregiver was the staff member assigned to the front 
desk of the clinic. A script for the introduction of the study was given to the staff member 
(Appendix H). The educational intervention planned was outlined by script (Appendix L) with 
 
 
 
 18 
the parent/caregiver of the adolescent regarding the HPV vaccine. The PI answered any 
questions the parent/caregiver had regarding the vaccine. The primary investigator reviewed the 
educational pamphlet (Appendix G) with the patient. Any questions or concerns were addressed 
during the discussion.  
Step 1.  Staff member at the front desk distributed the cover letter provided (Appendix 
C). The cover letter was given to the parent/caregiver of adolescents in the identified age group.   
Step 2.  The child and caregiver were placed in an exam room by the medical assistant 
(MA). The MA provided the educational pamphlet to parent/caregiver (Appendix G). The 
parent/caregiver was instructed to review the material. The PI was invited in only if the 
parent/caregiver gave verbal agreement to participate in the study. The RN or MA notified the PI 
of the verbal agreement.  Pre-educational survey (Appendix E) was given to the parent/caregiver 
per the PI if they were interested in the study.  
Step 3.  The primary investigator ensured that the parent/caregiver understood the study 
and confirmed by verbalizing understanding, per a verbal response from the parent/caregiver. A 
verbal response had to include an answer of yes or no to the question: “Do you understand the 
study?” Answering yes to the question was considered as verbal understanding of the study. The 
PI requested that the pre-educational intervention survey be filled out prior to beginning the 
educational intervention with the parent/caregiver.  
Step 4.  The educational intervention occurred prior to the office visit with the provider, 
after the patient had been roomed and was waiting for the provider. The goal was to speak with 
the parent/caregiver prior to their interaction with the provider.  However, consideration of clinic 
flow and provider schedules was always a priority, so at times the PI spoke with the 
parent/caregiver after the provider visit was complete. The PI discussed the vaccine with the 
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parent/caregiver, using the educational pamphlet as the guide. Any questions regarding the 
vaccine were discussed. The educational pamphlet was reviewed (Appendix G). The script for 
this discussion is attached (Appendix L). All questions regarding the vaccine were answered by 
the PI, who is a licensed RN and DNP-FNP student.  
Step 5.  After discussing the vaccine and addressing all questions the parent/caregiver 
had, the parent/caregiver of the adolescent was then asked about their intent to vaccinate. The PI 
provided a post-educational intervention survey to be completed by the parent/caregiver 
(Appendix F). The decision to vaccinate was documented by the PI. The parent/caregiver was 
asked to leave the pre-/post- educational intervention surveys in the exam room after the visit to 
be collected by the PI.  If the parent/caregiver chose to receive vaccination, the PI facilitated 
vaccine initiation by informing the provider who then ordered the vaccine administration to be 
given by the certified MA/RN.  
Step 6.  The pre- and post- educational intervention surveys (Appendix E and Appendix 
F) were used to evaluate whether the educational intervention increased first dose administration 
of the HPV vaccine and was successful in overcoming child/parent knowledge barriers of the 
HPV vaccine.  
Phase 4 - Chart Review  
After one month of providing the educational intervention to parent/caregivers of the 
adolescents aged 11-17 years old, a follow-up chart review evaluated post-intervention rates 
(Phase 4). Data were collected from 100 charts selected by convenience sampling technique to 
determine if the vaccination goal was met using the same chart audit tool (Appendix D) for post 
assessment. The charts were selected by convenience sampling technique from children aged 11-
17 years old that were seen in the clinic by a provider during the time- period of January 15, 
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2020 to February 15, 2020. Data were collected from the charts, included patient age, gender, 
and race, whether counseling was offered regarding HPV vaccination, by whom, whether the 
HPV vaccine was offered, whether the patient accepted/refused/deferred vaccination, whether 
the HPV vaccine series was initiated, and whether the HPV vaccine series was completed. Data 
were collected from the chart audits by the PI.  The survey data were entered into SPSS, version 
25, and analyzed by a statistician. The St. Vincent (Ascension) Institutional Review Board 
granted approval (#R20190145) prior to the start of this project.  
Instruments 
Parent/Child Pre-Educational and Post- Educational Intervention Surveys. 
Parent/Caregiver knowledge of the HPV vaccine and parent/caregiver intent to initiate 
the HPV vaccination was measured by an investigator-developed instrument called the 
Parent/Child Pre-Educational Intervention Survey.  This is a 6-item survey.  Two items are 
answered with “yes/no” responses, two are answered with “true/false” responses, and two are 
answers with a 10-point Likert-type scale (with 0 being no chance and 10 very likely). The pre-
educational survey was designed to measure knowledge of the HPV vaccine and intent to 
vaccinate prior to the educational intervention. The Post- Educational Intervention Survey was 
the same as the Pre-educational Intervention Survey for questions 2-4, and then the post- survey 
added questions 5-7 that were designed to measure intent to administer the vaccine after an 
educational intervention was given. The final question asked if the RN led educational 
intervention was helpful in their decision to vaccinate their child? 
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Improving Rates of First Dose Administration of the HPV vaccine Chart Audit 
Tool. 
Chart audits were conducted to determine the baseline vaccination rate for the clinic as 
well as the post-intervention vaccination rate for the clinic.  An instrument called the Improving 
Rates of First Dose Administration of the HPV Vaccine Chart Audit Tool was used to ensure 
consistency in data collection from randomly selected charts.  The following information was 
collected:  gender, age, race, whether counseling on the HPV vaccine was provided; whether the 
HPV vaccine was offered;  patient’s response if vaccine was offered;  whether the HPV vaccine 
series was initiated today;  whether the vaccine series initiated or completed prior to this visit;  
and the date documented for doses of the vaccine the child received prior to the study.   
Data Analysis 
Descriptive statistics were used to analyze variables such as age, gender, and ethnicity.  
HPV vaccination rates were examined pre- and post-educational intervention using Chi-square 
test.  Means of interval variables on the pre- and post-educational intervention survey responses 
were analyzed using an independent samples t-test. All data analysis was conducting using 
SPSS, version 25.  Microsoft Excel was used to create frequency tables.  
Results 
Phase 1:  Baseline Chart Review 
  The sample for the baseline chart audits were predominantly Caucasian (97%, n=97) and 
female (females 56%, n=56; males 44%, n=44) with the average age of 13.9 years (pre-, n=100, 
see Table 2). One hundred medical records were charts selected by convenience sampling 
technique dated October 15, 2019 through January 15, 2020 meeting age criteria 11-17 years old 
until a sufficient sample size of 100 was obtained.  Of the 100 charts selected by convenience 
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sampling technique, 100% were counseled by the provider who was an APRN, 100% were 
offered vaccine, and 19.1% (see Table 1) chose to be vaccinated.  
The results of the study were based on vaccination rates for those who had not received 
any of the vaccine series prior to this visit.  One hundred four children had received doses of the 
HPV vaccine through completion. There were 47 eligible charts for the pre-audit. Table 3 
presents data for those receiving their initial dose of the HPV vaccine before the intervention.  
From this total of 47, 9 had been vaccinated pre- intervention, leaving 38 who had chosen not to 
be vaccinated prior to the intervention.  
There were 15 caregivers in the intervention group.  Prior to the education intervention, 
parent/caregivers were given the opportunity to share their knowledge and intent to vaccinate 
with a pre-educational intervention survey (Appendix E) (Table 5). These parents/caregivers had 
high knowledge scores in the baseline assessment. In the pre-intervention surveys, most parents 
knew that it was recommended (80%), and felt it was a part of cancer prevention (100%); see 
Table 5).  Using a scale of 0-10, with 10 being absolutely planning to receive the vaccination that 
day and 0 not planning on receiving the vaccine at all.  To receive the vaccination today (M=4.3) 
or in the future (M=5.9, Table 2).  
Phase 2:  Chart Review 
The sample for the post- intervention chart audits were predominantly Caucasian (94%, 
n=94), and evenly split between females and males (females {50% n=50} and males {50%, 
n=50}), with the average age of 13.6 years (n=100) (see Table 2). Of the 100 charts selected by 
convenience sampling technique, 100% were counseled by the provider, the counseling was 
provided by an APRN, 100% were offered vaccine, and 40.8% (see Table 3) chose to be 
vaccinated.  
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Following the educational intervention parent/caregivers were given the opportunity to 
share feedback of the educational intervention (post-educational intervention survey, Appendix F) 
and their intent to vaccinate (Table 2 and Table 3). After the educational intervention, of those 
who did not complete their series of vaccination that day (n=96), there was a significant increase 
from 19.1% (pre-) to 40.8% (post-) who chose to be vaccinated with their initial dose of the HPV 
vaccine (p=0.21; see Table 1).  According to the pre- versus post- educational intervention results, 
satisfaction overall with helpfulness, on a scale of 0-10 with 10 being the most helpful, parents 
thought the intervention was helpful (M=9.3, SD=1.3), the pamphlet was helpful (M=9.4, SD 1.3), 
and the principal investigator discussion was helpful (9.7, SD 1.0) (See Table 5). 
The results of the study were based on vaccination rates for those who had not received 
any of the vaccine series prior to this visit.  One hundred four children had received doses of the 
HPV vaccine through completion. There were 49 eligible charts to review for the post-audit.  Table 
3 presents data for those receiving their initial dose of the HPV vaccine before and after the 
intervention. Per the chart reviews out of 49 total, there were 20 post- intervention patients that 
chose to be vaccinated and 29 chose not to be vaccinated. This shows a significant increase, from 
19.1% to 40.8% for those who received their first dose of the vaccine. Unfortunately, there is no 
way to tell which part of the convenience sample post- intervention received the educational 
intervention.   
 Table 4 presents the data for the pre- and post- intervention vaccination rates. Prior to the 
educational intervention, the clinic reported their vaccination rates at 58.4% of adolescents who 
had received some or all of their vaccination series. The clinic monthly rate for vaccination for 
February 2020, following the study, was 64.3% (p= .044), see Table 4).  These results indicate the 
clinic surpassed their goal of 60% after the intervention was provided in the clinic.   
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Discussion 
The purpose of this study was to evaluate the effect the effect of an RN-led educational 
intervention and the impact of the intervention on the intent to vaccinate and vaccination rates in 
a specific pediatric primary care setting.  The HPV vaccination rates for the initial dose of the 
vaccine increased from 19.1% to 40.8% (p=.21, see Table 3) and for any dose from 58.4% to 
64.3% (p=.044, see Table 4).  These results indicate the clinic surpassed its’ goal of 60% after 
the intervention was provided. The increase in parents/caregivers choosing to vaccinate their 
child after the educational intervention suggests that the intervention may have led to an increase 
in vaccination rates. Although this study was not designed to test for causation, it is encouraging 
that there was a significant improvement in vaccination rates after a brief and simple educational 
session with the parent/caregivers. Because baseline knowledge scores were already high and 
perceptions started out positive, it is not likely the parent/caregivers learned new information; 
however, it is possible that simply discussing the HPV vaccine brought it to the forefront of their 
attention and thus made them more likely to vaccinate.  
The finding of improved vaccination rates for both first dose and consecutive doses of the 
HPV vaccine are encouraging, however rates are still well below the national goal of 80% 
(Harris, 2017), and this low rate may lead to preventable morbidity and mortality related to HPV 
cancers.  There could be many reasons for the rates remaining low; including religious or 
personal beliefs regarding vaccinations, and the lack of understanding of the reasoning behind 
initiating the series at such a young age (Vadaparamil, 2014).  It is also supported in the 
literature that the barriers that exist can be overcome by increasing education to caregivers 
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(Vadaparamil, 2014). It is likely that the brief education to caregivers may have played a role 
with the increase in rates.  However, knowledge is a necessary, but not sufficient, precursor to 
decision-making and future studies should expand beyond just knowledge barriers. Further 
investigation is needed to identify how to overcome those perceptions and what specific element 
of the session led to the improvement in rates.  Vaccination rates improved after a 1:1 10-15 
minute educational discussion between the caregiver and the RN; this finding suggests that the 
1:1 interaction to discuss facts and answer questions can improve vaccination rates. Additionally, 
satisfaction scores when rating helpfulness were high, suggesting positive interaction between 
the parent/caregiver and provider. Next steps would include how to best incorporate this 1:1 
educational opportunity into standard practice.  
The finding of low vaccination rates is consistent with the national average of 
approximately 60% of girls and boys, ages 13 to 17 years who have received only one dose of 
the HPV vaccination (Smulian, Mitchell, & Stokley, 2016), but it is encouraging that this clinic 
increased rates from 19.1% to 40.8% (see Table 3), which is now closer to meeting the national 
average. Another recommendation would be to change the educational intervention to make it 
more interactive with both the parent and the child (Dempsey, 2019).  This educational session 
took the PI around 10-15 mins to provide.  It was an open discussion, although the child was 
present, the discussion was directed towards the caregiver. During the 1:1 discussion the PI 
clarified and allowed the parent to ask any questions they had about the HPV vaccine. During the 
educational sessions some of the barriers, misperceptions, and concerns expressed by the 
caregivers included:  lack of benefit for their child, perception of their child being low risk, they 
did not understand why the HPV vaccine was initiated at such a young age, and they felt the 
HPV vaccine was falsely advertised.  Using proper engagement methods, aimed towards 
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involving both participants, is important to ensure both the parent and child understand the 
education being provided.  
The parent/caregiver participants in this study all had good baseline knowledge scores 
and positive perceptions about the importance of administering the HPV vaccine, which suggests  
that they are knowledgeable, willing, and able to complete the first dose administration of the 
HPV vaccine. However, time to provide education regarding the vaccine appears to be a 
significant barrier that needs to be addressed for the providers in the clinical setting.  
In a study by Carhart (2018), time constraint and inconsistent or lack of recommendation 
by the health care provider (HCP) were found to be barriers to parents’ decision to vaccinate. 
One stakeholder in the study stated that providers are not making the strong recommendation for 
the vaccine and organizations are not holding them accountable (Carhart, 2018). This is a barrier 
in a lot of places, but in the study site the providers recommended it 100% of the time.  
Therefore, provider recommendation is not a reason for low rates in this clinic, therefore, other 
factors need to be considered.  
The vaccine has had a huge impact on preventing HPV, yet vaccination rates remain low 
despite the strong evidence to support how it prevents cervical cancers and related morbidity and 
mortality rates (CDC, 2019). It is essential that we understand factors that influence the decision 
to vaccinate and implement evidence-based strategies to improve vaccination rates.  Several 
barriers to vaccination were identified in this study may be categorized as; provider- based, 
patient/caregiver- based, and system- based.   
Providers in the clinic recognized that they recommend the HPV vaccine most of the time, 
but do not have time to discuss these recommendations with parents in depth.  Patient/Caregiver 
barriers found in the literature reported parents needing more information before choosing to 
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vaccinate their child (Vadaparamil, 2014).  Parents in this study reported feeling the vaccination 
would have a negative effect on sexual behavior and most of them felt that their child’s risk of 
contracting HPV was low.  Other studies (Dempsey, 2019) and (Chuang, 2017), identified more 
barriers such as; social influences, irregular preventative care, and vaccine cost.  
System- based barriers include the absence of reminder systems and problems within the 
electronic health records.  It was identified by (Vadaparamil, 2014) that knowledge and 
perception of the HPV vaccine directly influenced caregiver intent and decision to vaccinate.  
Additionally, an evidence-based strategy to improve education and intent includes; offering a 1:1 
educational session between the healthcare provider and caregiver (Vadaparamil, 2014).  This 
strategy was used as a focus for this study.  
Providers may not offer the vaccine because they do not typically see children in the 
recommended age group of 11-17 years-old, for wellness visits.  When children 11-17 years-old 
are seen in the office it often occurs after sexual activity has been initiated. Providers 
acknowledged that it may be difficult for young adults to locate a healthcare provider who will 
accept and file insurance for the vaccinations.  
Another barrier reported (Vadaparamil, 2014) is that the providers have a difficult time 
getting adolescents to their appointment because they are usually healthy, and the parents do not 
seek wellness appointments for them. Many providers in the study reported addressing 
vaccination only at wellness visits; however, a few providers were trying to address it at all visits 
to avoid “missed opportunities.” Time constraint and the need to prioritize care, however, can 
limit how much is covered during an acute care visit. Time constraint was addressed in the study 
by limiting participants to only those seeking wellness, non-acute visits to limit the biasing effect 
of type of visits on results.   
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Family practice providers reported too many competing priorities, such as the requirement 
for patients to have depression screening versus providing vaccination recommendations 
(Carhart, 2018).  Even though providers have the intention of recommending the HPV vaccine, 
they may lose track and forget to do it (Carhart, 2018).  The study site had issues regarding HPV 
vaccination recommendation.   Providers found they had time to recommend the vaccine, but 
they reported difficulty finding time to provide education or answer questions regarding the 
vaccine. This may have left the parent/caregiver feeling uncertain at times and not ready to make 
decisions regarding vaccination, therefore, influencing vaccination rates negatively.  
Holman (2014) found that parental attitudes towards vaccination were a major barrier to 
providing the HPV vaccine to adolescents. For example, a significant number of parents in that 
study reported needing more information before vaccinating their children. The parents voiced 
concerns about the vaccine’s effect on sexual behavior and demonstrated a low perception of 
their children’s risk of contracting HPV. These parents also identified social influences, irregular 
preventive care, and vaccine cost as potential barriers.  Parents consistently cited health care 
professionals’ recommendations, and the information they provide, as one of the most important 
factors in their decision to vaccinate their children (Holman, 2014).  Vaccination rates for the 
study clinic improved when the RN provided a 1:1 brief educational discussion.  This finding 
suggests that the 1:1 interaction to discuss facts and answer questions can improve vaccination 
rates. 
In addition, parent/caregivers were very engaged during the educational intervention and 
appeared to appreciate knowing more about the vaccine. Further investigation is needed to 
determine what specific element of the educational intervention led to this improvement. Brief 
education for parents/caregivers may have played a major role in the increased vaccination rates. 
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Studies have shown that efforts such as increased education to parent/caregivers can increase 
HPV vaccination rates in the primary care setting (Dempsey, 2019).  
The increase in vaccination rates is a positive and encouraging finding from this study; 
however, the vaccination rates are still low and evidence-based strategies to sustain this 
improvement with educational opportunities are needed. An example of an effective sustainment 
strategy that worked well in other settings and would be appropriate in this study’s setting is 
increasing the use of audio-visual materials and improvement in IT technologies for education.  
Dempsey (2019) provided an intervention of a digital video in a study, then parents/caregivers 
viewed the video while waiting for the visit. This research suggested the education by video 
increased vaccination rates. Another strategy mentioned by Chuang (2017) could be included by 
using scorecards or monthly provider audits by an appointed team leader in the clinic to help 
providers keep track of their own vaccination rates. The study site utilizes an appointed leader to 
track these rates, therefore, contributing to a 100% recommendation rate for the providers in the 
clinic.  
 One of the leading approaches as an evidence-based strategy that helped improve HPV 
vaccination rates in the primary care setting is the use of information technology (IT). Dempsey 
(2019) found the use of an educational video in the waiting room to overcome knowledge 
barriers to receiving the HPV vaccine to be particularly helpful in the primary care setting.  
Clinics could also show an educational video to the parent/caregiver while waiting on the 
provider. In this study having a dedicated health care professional available to spend time with 
the parent/caregiver to provide education was effective as suggested by an increase in 
vaccination rates. The educational intervention did have a positive outcome, though not as 
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dramatic as anticipated. With a few modifications, the 10-15 minute education intervention could 
be incorporated in the surrounding pediatric clinics with minimal expenditure of cost or time.  
Other evidence-based strategies include empowerment of staff.  It is supported in the 
literature that any staff member, including a trained Medical Assistant (MA), could provide this 
education. It would cost a clinic approximately $73,000 to assign an RN this responsibility in 
comparison to a MA, who would cost around $34,000 (Chuang, 2017). Next steps should include 
how best to incorporate this or similar 1:1 educational opportunity into standard practice for all 
pediatric clinics. Future practice should include continued education for providers on using 
improved IT techniques, such as an interactive I- pad, or module that could be done prior to the 
patient visit to assess knowledge of HPV.  In addition, a policy change to consider, would be 
adding an educational printout to the mandatory school paperwork as a form that both 
adolescents and their caregivers could review that would provide necessary information 
regarding the HPV vaccine. These methods are time efficient and provide a collaborative 
approach that do not overburden the caregiver, provider, or office staff. These are all ways to 
improve the caregiver intent to vaccinate, therefore hopefully leading to a further increase in 
vaccinations.  
Implications for Practice 
Review of the literature suggested the need to explore the educational needs and methods 
utilized to provide education, among a variety of community settings (Chuang, 2017). Research 
also indicated that knowledge of the HPV vaccine and need for further education was warranted 
(Chuang, 2017).  Implementing a 1:1 educational session may have increased rates for this 
specific clinic, but a more robust longitudinal study would need to be conducted in the future. 
Next steps should include how best to incorporate this 1:1 educational opportunity into standard 
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practice. It is supported in the literature that any staff member, including an MA could provide 
this education. It would cost a clinic around $73,000 to assign an RN this responsibility in 
comparison to a MA, which would cost around $34,000 (Chuang, 2017).   
An evidence-based strategy that should be considered for practice is training and 
empowering staff to help streamline the process (Chuang, 2017).  Future practice should include 
continued education for providers on the importance of educating parent/caregivers of 
adolescents ages 11-17 years old, using improved IT techniques (Dempsey, 2019).  One way to 
remind providers to provide further education on the vaccine would be to place posters and 
prompts in the patient rooms and in their individual office spaces (Chuang, 2017). Another 
beneficial method would be for the MA/RN to give the parent/caregiver a copy of an educational 
pamphlet to review while waiting. Additionally, it would also be worthwhile to implement a 
tracking measure to monitor screening and education adherence. The study clinic utilizes a team 
member to track current vaccination rates and report them to providers, but they may benefit 
from education adherence being added to the electronic health records as a reminder.  
Limitations 
Limitations of this study included a small sample size of patients seen during this time 
period for non-acute visits, aged 11-17 years old.  It was emphasized by the clinic that their 
highest numbers of wellness visits occur from April to September; this study period was from 
October to February.  The increase of adolescent visits normally take place from April to the 
beginning of the new school year due to the need for sports physicals during that time. During 
the winter months there are an abundance of children seen for sick visits, so the numbers were 
considerably lower.   
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 The chart review method could have focused only on children that had never received a 
dose of the HPV vaccine. This result would have provided more concise data aimed towards the 
focus of this study.  Additionally, I did not assign a unique identifier to intervention participants, 
thus, participants were unable to be matched with survey responses.  This collection method 
would have helped the study match responses to decisions as to whether or not they chose to 
vaccinate. 
  In addition, this study took place at only one clinic over a period of a few months.  Other 
settings and/or other populations may have yielded different results. The results were not 
generalizable due to using a convenience sample.  This study took place at only one clinic over a 
period of a few months. Increasing the study reach to include multiple locations could have 
increased the number of parent/caregivers willing to participate in the study.  
Conclusion 
In conclusion, more than 90% of cervical cancer cases are caused by the human 
papilloma virus, and administration of the HPV vaccine to adolescents can reduce or eliminate 
this risk.  However, vaccination rates for HPV among adolescents are still very low, at only 60% 
vaccinated (Smulian, Mitchell, & Stokley, 2016).  A 1:1 educational discussion between the 
health care provider and the parent/caregiver is an effective evidence-based strategy that has 
improved vaccination rates in other studies, as well as the study described in this paper.  Health 
care providers are one of the most important factors that influence parental/caregiver vaccination 
decisions, and we need to make sure there is sufficient time and opportunity for this interaction 
to occur between the caregiver and the health care provider.  In addition to knowledge, 
misperceptions, and other barriers mentioned in this study, targeted interventions need to be 
determined and aimed towards eliminating these barriers for future studies.  
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Patients may only see their primary care provider once yearly or for sick visits, so 
educating the caregiver on the importance of vaccinating their child during these visits is 
essential, or they may go unvaccinated. Appropriate screening, overcoming parent/child 
knowledge barriers, and ultimately administration of the vaccine will decrease the incidence of 
HPV- related cancers (Harris, 2017).   
Health care providers are one of the most important factors that influence vaccination 
decisions (Holman, 2014).  This finding was supported in this study, thus, we need strategies that 
create ample opportunity for parents/caregivers to receive education and an opportunity for 
discussion with their health care providers.  Because of the significant impact HPV vaccination 
can have on health outcomes, providers and office staff must continue to make efforts to increase 
the intent to vaccinate for parents and caregivers. The educational intervention is a brief way of 
increasing awareness and intent to vaccinate for HPV in the primary care setting. Therefore, it is 
imperative that primary care providers work toward efforts to increase vaccination coverage. It is 
essential that health care providers and public health organizations initiate efforts to increase 
HPV vaccination doses through completion of the two or three-dose series (Smulian, Mitchell, & 
Stokley, 2016). 
  In this study after a brief educational intervention that focused on increasing intent to 
vaccinate, there was an increase in administration of the HPV vaccine. However, vaccination rates 
were still low and the longer-term vaccination rates remained unchanged. There remains much 
need for improvement. The preliminary results from this study are indeed promising however in 
the future, a longitudinal and more robust study needs to be done to see if the educational 
intervention contributed to this increase in vaccination rates.  Future work should seek to identify 
 
 
 
 34 
which specific elements of this intervention contributed to the success, and strategies to ensure 
sustainability of these improvements.  
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Appendix A.  Educational Intervention Outline 
 
With each non-acute visit meeting age criteria 11-17 years old: 
 
• Supportive staff will provide cover letter and educational pamphlet regarding HPV 
  vaccine to each parent/caregiver at the beginning of the visit. 
 
 
• The staff will reinforce that the primary investigator will be providing education on the 
kvaccine that same day 
 
 
• Any questions the parent/caregiver may have will be routed to the primary investigator 
 
• Parent/caregiver will be asked to read cover letter introducing the study. Parent/caregiver 
will also be requested to read educational pamphlet and decide if they are interested in the study 
with the PI.  
 
 
 
During each visit: 
 
• If parents/caregivers are interested in the study the primary investigator will receive 
verbal consent and educate willing parent/caregivers on receiving HPV vaccination. The  
PI will distribute the pre-educational intervention survey prior to starting the educational 
intervention. 
 
• The primary investigator will collect survey from parent/caregiver prior to beginning the 
educational intervention.  
 
• The parent/caregiver will be informed of the intent to have the child receive the HPV 
vaccine that day. 
 
• Any questions the parent/caregiver may have regarding the vaccine will be discussed.  
 
• If the parent/caregiver decide to wait on vaccination, it will be requested that they take 
the educational pamphlets home with them and set up a future appointment with the  
provider to discuss vaccine further.  
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Appendix B.  Consent Form 
 
 
Institutional Review Board 
AGREEMENT TO PARTICIPATE IN A RESEARCH STUDY 
MEDICAL RESEARCH INFORMED CONSENT 
Title of research study: Improving Rates of First Dose Administration of the HPV vaccine 
Investigator: Lindsey Brough, NP Primary Investigator and Scarlett Mikesell-Pierce UK DNP 
student Co-Investigator 
 
 
PARTICIPANT NAME ______________________________________________ 
 
Why am I being invited to take part in a research study? 
You are being invited to take part in a research study about overcoming parent/child knowledge 
barriers to receiving the HPV vaccination. You are being invited to take part in this research 
study because you are the parent/caregiver of an adolescent patient at St. Vincent Pediatric 
Clinic, where the study is taking place.  All parent/caregivers of patients meeting age criteria 11-
17 years old will be invited to participate in this study.  
What should I know about a research study? 
You will not get any personal benefit from taking part in this study. If you decide to take part in 
this study, it should be because you want to volunteer. Your adolescent will not lose any benefits 
or rights they would normally have if you choose not to volunteer. You can stop at any time 
during the study and keep the benefits and rights you had before volunteering.  
Why is this research being done? 
The purpose of this study is to increase first dose administration of the HPV vaccine by 
providing an educational intervention that increases parent/caregiver knowledge regarding the 
vaccine.  
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How long will the research last and what will I need to do? 
The research procedures will be conducted at St. Vincent Pediatric Clinic. The study will take 
place during normal clinic hours during your scheduled visit at the clinic.  You will not be asked 
to volunteer any additional time.  
Is there any way being in this study could be bad for me? 
The risks to participating in this study may include some emotional discomfort due to the nature 
of HPV. You may experience a previously unknown risk or side effect of HPV.  
Will being in this study help me in any way? 
You will not get any personal benefit from taking part in this study.  
What happens if I do not want to be in this research? 
If you do not wish to participate, there are no other choices except not to take part in the study.  
Who can I talk to? 
The person in charge of this study is Lindsey Brough, NP from St.Vincent Pediatric Clinic and 
Scarlett Mikesell-Pierce, BSN, RN of the University of Kentucky, College of Nursing. She is 
being guided in this research by Elizabeth Tovar, Phd, RN, FNP-C. There may be other people 
on the research team assisting at different times during the study.  
What happens if I say yes, I want to be in this research? 
You will be asked to participate in an educational intervention that discusses the HPV vaccine. 
Educational pamphlets will be provided. Any questions regarding the HPV vaccine will be 
answered and open for discussion.  
What happens if I say yes, but I change my mind later? 
You can leave the research at any time it will not be held against you. 
Is there any way being in this study could be bad for me? (Detailed Risks) 
The risks to participating in this study may include some emotional discomfort due to the nature 
of HPV. You may experience a previously unknown risk or side effect of HPV.  
What happens to the information collected for the research? 
We will make every effort to keep confidential all research records that identify you to the extent 
allowed by law.  
Your information will be combined with information from other people taking part in the study. 
When we write about the study to share it with other researchers, we will write about the 
combined information we have gathered. You will not be personally identified in these written 
materials. We may publish the results of this study; however, we will keep your name and other 
identifying information private.  
We will make every effort to prevent anyone who is not on the research team from knowing that 
you gave us information, or what the information is. No identifying information will be recorded 
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with the discussion, and this data will be password protected and only accessed by the principal 
investigator.  
You should know, however, that there are some circumstances in which we may have to show 
your information to other people. For example, the law may require us to show your information 
to a court or to tell authorities if you report information about a child being abused or if you pose 
a danger to yourself or someone else.  
Please be aware, while we make every effort to safeguard your data once received, given the 
nature of online information involving the internet, we can never guarantee the confidentiality of 
the data while still en route to us.  
Will the researchers benefit from my participation in this study? 
The researchers will not receive any rewards or payment for you taking part in this study.  
What else do I need to know? 
Before you decide whether to accept this invitation to take part in the study, please ask any 
questions that might come to mind now. Later, if you have questions, suggestions, concerns, or 
complaints about the study, you can contact the investigator, Scarlett Mikesell-Pierce (502) 644-
7849 or email at scarlett.mikesell@uky.edu. If you have any questions about your rights as a 
volunteer in this research, contact the staff in the St. Vincent IRB Office at 317-338-2194. We 
will give you a signed copy of this consent form to take with you.  
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Your signature documents your permission to take part in this research.  Please keep a copy of 
this Informed Consent for your records. 
   
Signature of subject  Date 
 
 
Printed name of subject 
   
Signature of person obtaining consent  Date 
  
Printed name of person obtaining consent   
 
 
 
 
   
Signature of Legally Authorized Representative  Date 
 
 Printed name of Legally Authorized Representative 
 
 
Check Relationship to Subject: 
 
  Legal Guardian or Legally Authorized Representative for Medical Care (LARM)     
  Spouse       Adult Son or Daughter   Mother or Father   Adult Brother or Sister 
  Other, explain: 
 
Reason subject is unable to sign for self: 
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RESEARCH PATIENT BILL OF RIGHTS 
 
 
I have been asked to participate in a research study.  Before I make a decision on whether 
or not I want to participate in this study, I have the right: 
 
1. To be told the reason why this study is being done. 
 
2. To be told how the study will be done and what kind of medication or 
device will be used 
 
3. To know the different types of side effects to expect from my participation 
in the study. 
 
4. To know what benefits I will receive from my participation in this study. 
 
5. To be told what other treatment is available for me, including the risks and 
benefits. 
 
6. To be told what other treatments are available to me after the study has 
been completed. 
 
7. To be given an opportunity to ask any questions concerning the medical 
experiment or the procedures involved. 
 
8. To stop the study at any time and know I will continue to receive good 
care. 
 
9. To receive a copy of the patient rights and the signed and dated informed 
consent form. 
 
10. To make up my mind about being part of the study without feeling forced 
to participate. 
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Appendix C.  Cover Letter      
 
Cover Letter 
 To Participant: 
My name is Scarlett Mikesell-Pierce of the University of Kentucky, College of 
Nursing and I am being guided in research by Lindsey Brough, NP at St. Vincent 
Pediatric clinic and Elizabeth Tovar, PhD, RN, FNP-C. There are no institution(s) or 
companies involved in the study through funding or financial support, cooperative 
research, or by providing equipment or materials for this study. 
I am inviting you to take part in a research study about human papilloma virus (HPV) 
vaccination. You will be asked to complete a short survey/questionnaire before and 
after a brief educational discussion about HPV vaccination. The 
surveys/questionnaires will help me to gain information about your understanding and 
knowledge regarding the HPV vaccine.  Each survey will take about 2-5 minutes to 
complete and the educational discussion will take about 10 minutes. I hope to make 
evidence-based recommendations from the survey results on ways to increase your 
knowledge and overcome barriers in the clinic regarding the HPV vaccination.  
Although you will not get personal benefit from taking part in this research study, 
your responses may help us understand more of the barriers that parents/children 
encounter when recommended the HPV vaccine.  
We hope to receive completed questionnaires from all the patients in the identified 
age group at St. Vincent Pediatric Clinic, and your answers are important to us. Of 
course, you have a choice about whether or not to complete the survey/questionnaire, 
but if you do participate, you are free to skip any questions or discontinue at any time. 
Participation in this study is voluntary, and if you do not choose to complete the 
survey there will no penalties or loss of benefits. If you do not wish to complete this 
survey, there are no alternative surveys. 
Your response to the survey is anonymous which means no names will appear or be 
used on research documents, or be used in presentations or publications. Your name 
will not be recorded on the surveys.  
If you have questions about the study, please feel free to ask; my contact information 
is given below. If you have complaints, suggestions, or questions about your rights as 
a research volunteer, contact the staff in the St. Vincent IRB at 317-338-2194.  Thank 
you in advance for your assistance with this important project. Please complete the 
pre-education survey if you want to participate in the study.  
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Sincerely, 
Scarlett Mikesell-Pierce, BSN, RN 
College of Nursing, University of Kentucky 
PHONE: 502-644-7849 
E-MAIL: scarlett.mikesell@uky.edu 
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Appendix D. Chart Audit Tool 
 
Improving Rates of First Dose Administration of the HPV vaccine 
Chart Audit Tool 
 
Study number:_______________ 
Gender:_____________________ 
Age:________________________ 
Race:_______________________ 
 
 
At the patient’s 11/12 year old well-child visit, were the following documented: 
 
 
Information Yes No Comments 
Was counseling on 
the HPV vaccine 
provided? 
 
 
By: ___ CMA 
      ____NP/MD 
  
Was the HPV 
vaccine offered? 
 
   
Patient’s response 
if vaccine was 
offered 
__ Accepted 
__ Deferred 
__ Declined 
  
Was the HPV 
vaccine series 
initiated today? 
   
Was the vaccine 
series initiated or 
completed prior to 
this visit? 
   
 
Doses given (Y/N)? #1_________           #2__________   
To ages 11-14           On-time?    Y/N  Y/N  
    
 
 
Doses given (Y/N)? #1_________           #2__________  #3_________ 
To ages 15-17           On-time?    Y/N  Y/N       Y/N 
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Appendix E.  Parent/Child Pre-Educational Intervention Survey 
 
Parent/Child Pre- Educational Intervention Survey 
 
Please circle your response:  
 
 
1. Have you heard of the HPV vaccine?            YES          NO 
 
 
2. The HPV vaccine is recommended for children 11-17 years of age.         TRUE       
FALSE 
 
3. The HPV vaccine is recommended for cancer prevention caused by the human papilloma 
virus.         TRUE      FALSE 
 
 
4. Were you planning on getting the HPV vaccine today?         YES        NO 
 
 
5. How likely are you to get the vaccine today? Rate on scale 0-10 (0 being no chance and 
10 very likely)  
 
0     1    2   3   4   5   6   7   8   9   10 
 
6. How likely are you to get the vaccine at some point in the future? Rate on scale 0-10 (0 
being no chance and 10 very likely) 
 
     0     1    2   3   4   5   6   7   8   9   10 
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Appendix F.  Parent/Child Post-Educational Intervention Survey 
 
Parent/Child Post- Educational Intervention Survey 
 
Please circle your response:  
 
 
1. Are you more familiar with the HPV vaccine?            YES          NO 
 
 
2. Were you planning on getting the HPV vaccine today?         YES        NO 
 
 
3. How likely are you to get the vaccine today? Rate on scale 0-10 (0 being no chance and 
10 very likely)  
 
0     1    2   3   4   5   6   7   8   9   10 
 
4. How likely are you to get the vaccine at some point in the future? Rate on scale 0-10 (0 
being no chance and 10 very likely) 
 
0     1    2   3   4   5   6   7   8   9   10 
 
5. How helpful was the educational discussion in helping answer your questions regarding 
the HPV vaccine? Rate on scale 0-10 (0 being not helpful and 10 being very helpful) 
 
0     1    2   3   4   5   6   7   8   9   10 
 
6. How helpful was the HPV educational pamphlet? Rate on scale 0-10 (0 being not helpful 
and 10 being extremely helpful) 
 
0     1    2   3   4   5   6   7   8   9   10 
 
7. How helpful was the discussion with the primary investigator? Rate on scale 0-10 (0 
being not helpful at all and 10 extremely helpful) 
0     1    2   3   4   5   6   7   8   9   10 
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Appendix G.  Educational Pamphlet 
 
 
 
The more we learn about health risks for our children, the more 
we can do to help protect them as they grow up. That’s why it’s so 
important to get the facts about human papillomavirus (HPV).5
THERE’S MORE TO LEARN ABOUT HPV ON THE OTHER SIDE. PROVIDED AS AN EDUCATIONAL RESOURCE BY MERCK.
         @HPV. EDUCATING PARENTS ABOUT RELATED CANCERS.       @KNOWHPVFOLLOW US ON:
A PARENT NEEDS TO
KNOW ABOUT HPV
THINGS
5
These can develop very slowly and may 
not even occur until later in life.
HPV can cause certain 
precancers, cancers,
and other diseases.
2
HPV is a little virus that can 
have big consequences. 
HPV infects both genders.
Both males and females can be 
infected with HPV. Exposure to the virus 
can happen with any kind of adolescent 
experimentation that involves genital 
contact with someone who has HPV — 
intercourse isn’t necessary, but it is the 
most common way to get the virus.
HPV can be spread even when 
someone with the virus has
no signs or symptoms.
3
1
Being informed is the fi rst step in 
helping protect your child.
4
The CDC and the American Cancer Society 
recommend HPV vaccination for girls and boys 
ages 11–12.
It’s important to talk to your child’s 
doctor before they are at risk. 
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Appendix H.  Staff Member Script for Introduction of Study 
 
Staff member Script for introduction of study 
 
Welcome 
 
Introduction   
 
There is a UK DNP student, Scarlett Mikesell-Pierce, currently working with the St. Vincent 
Pediatric Clinic to help us increase our vaccination rates for the HPV vaccine.  Here is some 
information regarding the study.  She will plan to meet with you prior to your visit with the 
provider today. Please read through the study while waiting for the provider so that she can 
address any questions you might have.  
 
Conclusion 
 
Please let me know if you have any questions while you are waiting.  
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Appendix I.  HIPPA for Research Purposes 
 
AUTHORIZATION TO USE AND DISCLOSE PROTECTED HEALTH INFORMATION FOR 
RESEARCH PURPOSES  
St.Vincent is dedicated to protecting the privacy rights of patients. Any uses and disclosures of personal health 
information are in accordance with a law called the Health Insurance Portability and Accountability Act of 1996 as 
amended by the Health Information Technology for Economic and Clinical Health Act (“HIPAA”). HIPAA is 
designed to protect the confidentiality of your health information. This document explains how your health 
information will be used and disclosed for the purposes of conducting, monitoring and auditing this study and 
describes your rights with respect to that information.  
Your personal health information is information about you that could be used to identify you, such as your name, 
address, telephone number, photograph, date of birth, social security number, new and existing medical records, 
DNA samples, or the types, dates and results of various tests and procedures. This may include information in your 
medical and hospital records, as well as information created or collected during the study.  
By signing this document you authorize the study physicians and St.Vincent Health and employees (collectively and 
individually “Researchers”) to use and disclose the following information about you to each other, the study sponsor 
and its representatives, the St.Vincent Health Institutional Review Board, and governmental agencies responsible for 
the oversight of this study, including the Food and Drug Administration and any foreign agencies as necessary: 
personal health information in your medical and hospital record including medical/surgical history, past and current 
medications, vital signs, physical examinations and laboratory results, other assessments, photographs and samples 
and analyses of blood, DNA and/or wounds. Your personal health information will be used to conduct the research 
study as described in the Informed Consent.  
You will not be allowed to review the information collected for the study until after the study is completed. When 
the study is over you will have access to the information again.  
St.Vincent Health will not condition treatment or payment on whether or not you sign this document. However, this 
document is required if you want to participate in the study.  
Your authorization to disclose your personal health information in connection with the study will expire at the end 
of the study and after all study-related data has been transferred to the sponsor. You may revoke your authorization 
to use your personal health information for the study in writing at any time by writing to the St.Vincent Health 
Institutional Review Board at 8402 Harcourt Road, Suite 806, Indianapolis, Indiana 46260. You understand that if 
St.Vincent Health has already taken action in reliance on your authorization they do not have to undo that action. If 
you revoke your authorization to use and disclose personal health information in connection with the study, you will 
no longer be able to participate in the study.  
Once information is disclosed, it can no longer be controlled by the study physician, St.Vincent Health or by you 
and may be re-disclosed by the recipient. Thus, your information would no longer be protected by HIPAA.  
A copy of this document will be placed in your medical record and you will receive a copy.  
If results of this study or future research you have authorized are published or reported in medical journals or at 
meetings, your name will not be included.  
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By signing this document, you acknowledge that you have read and understand this Authorization. Further, you 
authorize the Researchers to use or disclose your health information in accordance with the terms of this 
Authorization.  
 
Printed name of subject 
Signature of subject/ authorized legal representative Relationship of authorized legal representative to subject  
TMP-509 HIPAA Authorization 
St. Vincent Health Institutional Review Board Form Rev. 03/2018  
//  
Subject’s Date of Birth (mm/dd/yyyy)  
Date 
XXX-XX- 
Subject’s Social Security Number (last 4 digits only)  
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Appendix J.  Staff Meeting Invitation 
 
Staff Meeting Invitation 
 
St. Vincent Pediatric Clinic Staff Members 
Attention to Providers  
Nurses 
Medical Assistants 
and Front desk staff only 
 
Research Staff Meeting 
“Improving Rates of First Dose Administration of 
the HPV vaccine” 
 
The purpose of this staff meeting is to inform clinic staff of the 
educational intervention that will be taking place in the office 
regarding overcoming parent/caregiver knowledge barriers of the 
HPV vaccination.  
Date    TBA 
Time    TBA 
Location St. Vincent Pediatric Clinic 
   Salem, IN  
Lunch will be provided to participating staff 
 
For additional information, please contact: 
Scarlett Mikesell-Pierce, BSN, RN 
(502) 644-7849 
 
 
 
 
 
 
 52 
Appendix K.  Staff Meeting Agenda        
Improving Rates of First Dose Administration of the HPV Vaccine 
Staff meeting agenda 
Welcome 
Thank you for coming to the staff meeting. I appreciate you being here so that I can inform you 
of the research study that is going to be taking place in this clinic.   
Introduction 
Introduction of principal investigator 
Statement of Purpose 
I am conducting this staff meeting to share information that I learned from the chart review and 
to discover barriers in this practice that affect recommendation of the HPV vaccine to patients. 
Your honest input is important and appreciated.  
Brief Review of Chart Review Findings 
5-10 minute presentation of chart review previously conducted on 11-17-year-old patients 
presenting to the clinic for non-acute visits.  This chart review will focus on whether the patients 
were counseled on the HPV vaccine, whether the vaccine was offered, whether it was 
accepted/declined/deferred, and whether it was initiated. Some demographic data including 
gender, age, and race will also be recorded. The staff will be informed of my plans to provide an 
educational intervention to the parent/caregivers that are willing to participate regarding the HPV 
vaccination. Copies of the pre-/post- surveys and educational pamphlet will be available for staff 
to review, so they are aware of the tools that I will be using to collect data during the study.  
Conclusion 
Any further questions/concerns and thank participants again for their contributions.  
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Appendix L.  Script for Parent/Caregiver Educational Intervention 
 
Script for Parent/Caregiver Educational Intervention  
 
To participant:   
 
My name is Scarlett Mikesell-Pierce of the University of Kentucky, College of Nursing and I am 
being guided in research by Lindsey Brough, NP at St. Vincent Pediatric clinic and Dr. Elizabeth 
Tovar, PhD, RN, FNP-C.  
 
This is a study about the facilitators and barriers that parents/caregivers encounter when 
recommended to receive the human papillomavirus (HPV) vaccine for their adolescent child. I 
am planning to provide some educational resources with intent to have your child vaccinated for 
HPV. I am available to answer any questions you may have regarding the HPV vaccine.  
 
Of course, you have a choice whether to participate in this educational intervention, but if you do 
participate, you are free to ask any questions regarding the vaccine. You can choose to 
discontinue this study at any time as well. Participation in this study is voluntary, and if you do 
not choose to be vaccinated there will be no penalties or loss of benefits.  
 
Your risk to participating in this study is minimal. Your risk may include emotional discomfort 
due to the nature of the vaccine and the development of HPV. Although we tried to minimize 
this, some of the discussion may make you feel uncomfortable.  
 
The discussion with myself regarding the HPV vaccine is anonymous which means no names 
will appear or be used for research documents, or be used in presentations or publications. The 
research team will not know that any information you provided came from you, not even whether 
you participated in the study.  
 
If you have any questions about the study, please feel free to ask; my contact information is 
given below. If you have any complaints, suggestions, or questions about the rights as a research 
volunteer, contact the staff in the St. Vincent IRB at 317-338-2194. 
 
Thank you in advance for your assistance with this important project.  
 
 
Sincerely,  
Scarlett Mikesell-Pierce, BSN,RN 
College of Nursing, University of Kentucky 
PHONE: 502-644-7849 
E-MAIL: scarlett.mikesell@uky.edu    
          
 
 
 
 
 
 
 
 54 
Table 1. Pre- and Post-Educational Intervention Chart Review 
 
Study Demographics 
 
  Phase 1 –Pre 
% 
(N=100) 
Phase 4 – 
Post 
% 
(N=100) 
p value  
Gender 
Male 
Female 
  
44% 
56% 
  
  
50% 
50% 
.40 
Race 
Caucasian 
African-American 
Hispanic 
  
  
97% 
1% 
2% 
  
  
  
94% 
4% 
2% 
.40 
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Table 2. Pre- and Post-Educational Intervention Surveys  
 
Intent to Vaccinate 
 
  Pre-education 
N (%) or Mean (SD) 
(N = 15) 
Post-education 
N (%) or Mean (SD) 
(N = 15) 
p 
Planning on getting vaccinated at 
today’s appointment 
   Yes 
   No 
   
  
5 (33%) 
10 (67%) 
  
  
 3 (20%) 
12 (80%) 
.41 
Likelihood of getting vaccine 
today (0-10) 4.3 (4.5) 6.7 (4.9) .20 
Likelihood of getting vaccine in 
the future (0-10) 
5.9 (4.8) 6.9 (4.1) .52 
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Table 3. Vaccination rates for administration of the HPV vaccine 
 
Chart Audits Pre- and Post- 
 
  Pre-
education 
N (%) 
Post-
education 
N (%) 
p 
Vaccinated 9 (19.1%) 20 (40.8%) .021* 
Not Vaccinated 38 (80.9%) 29 (59.2%)   
Total 47 (100%) 49 (100%)   
 
 
Table 4. Pre- and Post- Clinic Vaccination Rates 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
  Pre-education 
n (%) 
Post-education 
n (%) 
p 
Vaccinated 303 (58.4%) 345 (64.3%) .044 
Not 
Vaccinated 
216 (41.6%) 357 (59.2%)    
Total 520 (100%) 535 (100%)   
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Table 5. Pre-educational intervention knowledge of the HPV vaccine, (N=15) 
 
Intervention Group 
 
Question Pre-education 
N  (%) 
Heard of the HPV vaccination 
   Yes 
   No 
  
12 (80%) 
3 (20%) 
The HPV vaccine is recommended for children 11-17 years of age 
   True  
   False 
  
12 (80%) 
3 (20%) 
The HPV vaccine is recommended for cancer prevention caused by the 
human papilloma virus? 
   True 
   False 
  
  
15 (100%) 
0 (0%) 
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Table 6. Post- Educational Intervention Survey Results 
 
Question Mean SD 
How helpful was the educational discussion? (use scale 0-10, 
with 0 being not helpful and 10 being very helpful) 
    
9.27 
  
1.3 
How helpful was the educational HPV pamphlet? (0-10) 9.4 
  
1.3 
How helpful was the discussion with the principal 
investigator? (0-10) 
9.73 
  
  
1.0 
 
 
 
 
 
 
